Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.16 (+3.57%), Market cap $0.02B, 52-week low–high $4.25 ~ $15.70.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a pare
Financial statements, price targets, institutional (13F) holdings and related news for Cadrenal Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Cadrenal Therapeutics, Inc. Common Stock trades at $1.16 (+3.57%). Real-time quotes and charts are available on BlackAll Trade.
Cadrenal Therapeutics, Inc. Common Stock has a market cap of about $0.02B.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin